Patents by Inventor Henryk T. Dudek

Henryk T. Dudek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF COMPLEMENT COMPONENT 5(C5) BY DOUBLE-STRANDED RNA
    Publication number: 20210139903
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing C5 target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: December 17, 2020
    Publication date: May 13, 2021
    Inventors: Bob D. BROWN, Henryk T. DUDEK
  • METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ANTITHROMBIN 3 (AT3) BY DOUBLE-STRANDED RNA
    Publication number: 20210095279
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing AT3 target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: February 28, 2020
    Publication date: April 1, 2021
    Inventors: Bob D. BROWN, Henryk T. DUDEK
  • Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA
    Patent number: 10954517
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing C5 target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: March 23, 2021
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • METHODS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF LDHA
    Publication number: 20210062199
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing LDHA expression, particularly in hepatocytes.
    Type: Application
    Filed: September 16, 2020
    Publication date: March 4, 2021
    Inventors: Bob D. BROWN, Henryk T. DUDEK, Utsav SAXENA, Natalie PURSELL, Cheng LAI, Weimin WANG, Rachel STORR, Naim NAZEF, Boyoung KIM
  • COMPOSITIONS AND METHODS FOR INHIBITING GYS2 EXPRESSION
    Publication number: 20210062197
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing GYS2 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of GYS2 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of GYS2 expression may also include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat glycogen storage diseases (e.g., GSDIa, GSDIII, GSDIV, GSDVI, and GSDIX) and related conditions.
    Type: Application
    Filed: February 15, 2019
    Publication date: March 4, 2021
    Inventors: Bob D. BROWN, Natalie PURSELL, Henryk T. DUDEK, Cheng LAI
  • Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
    Patent number: 10844381
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: November 24, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • METHODS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF LDHA
    Publication number: 20200283775
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing LDHA expression, particularly in hepatocytes.
    Type: Application
    Filed: October 12, 2018
    Publication date: September 10, 2020
    Inventors: Bob D. BROWN, Henryk T. DUDEK, Utsav SAXENA, Natalie PURSELL, Cheng LAI, Weimin WANG, Rachel STORR, Naim NAZEF, Boyoung KIM
  • Therapeutic inhibition of lactate dehydrogenase and agents therefor
    Patent number: 10738311
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing lactact dehydrogenase target RNA and protein levels via use of ds RNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: August 11, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek, Cheng Lai
  • Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA
    Patent number: 10689647
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing AT3 target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: June 23, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
    Patent number: 10676742
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing transth:yretin (TTR) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: June 9, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Methods and compositions for the specific inhibition of ?-catenin by double-stranded RNA
    Patent number: 10612023
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-catenin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: April 7, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GLYCOLATE OXIDASE (HAO1) BY DOUBLE-STRANDED RNA
    Publication number: 20200002705
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: August 20, 2019
    Publication date: January 2, 2020
    Applicant: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF APLHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA
    Publication number: 20190390198
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: June 28, 2019
    Publication date: December 26, 2019
    Applicant: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
    Patent number: 10487330
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: November 26, 2019
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
    Patent number: 10465195
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: November 5, 2019
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR
    Publication number: 20190323014
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing lactact dehydrogenase target RNA and protein levels via use of ds RNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: March 15, 2019
    Publication date: October 24, 2019
    Applicant: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek, Cheng Lai
  • Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
    Patent number: 10435692
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: October 8, 2019
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
    Patent number: 10370655
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: August 6, 2019
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF COMPLEMENT COMPONENT 5(C5) BY DOUBLE-STRANDED RNA
    Publication number: 20190218550
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing C5 target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: December 14, 2018
    Publication date: July 18, 2019
    Applicant: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Therapeutic inhibition of lactate dehydrogenase and agents therefor
    Patent number: 10351854
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: July 16, 2019
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek, Cheng Lai